Piramal Pharma Solutions (PPS), a contract development and manufacturing organization, is investing $55 million across its sites in North America and Asia to expand its active pharmaceutical ingredient (API) manufacturing capabilities and capacities.

A part of this investment will go into new multi-purpose plants, with over 270 kilo liters of total capacity, to support PPS’ pipeline of approximately 80 late-stage programs.  PPS will also expand its plant in Riverview, Michigan while augmenting its early-development capabilities at its facility in Ennore, India through additions of GMP kilo labs and a pilot plant. 

PPS will add early development capabilities in both drug substance and drug product out of its Morpeth, UK facility. Support functions such as analytical capabilities, research and development infrastructure, automation, and IT systems will also be expanded at all API sites through this investment.

PPS supports API development and manufacturing through an integrated model across its five sites in North America, Europe, and Asia. API development activities, including route scouting and process development, are conducted at the company’s facilities in Riverview, Ennore and Aurora, California. These facilities are forward integrated with commercial API manufacturing units at Aurora; Ennore; Riverview; Morpeth; and Digwal, India.

Source: Piramal Pharma Solutions